1. Medtech Insight
  2. >>Archive

Research Briefs: Updates From EndoGastric Solutions, Cordis, Aptus Endosystems

RESPECT trial is designed to provide the kind of Level 1 evidence EndoGastic Solutions needs to persuade payers and physicians of the benefits of the EsophyX GERD-repair device. Cordis and Aptus Endosystems release new data at the Vascular Interventional Advances (VIVA) 2013 annual meeting in Las Vegas.

EndoGastric Solutions Inc. announced Oct. 8 that it has completed enrollment for the Randomized EsophyX vs. Sham/Placebo Controlled Trial (RESPECT

) with more than the originally planned 120 patients. RESPECT is designed to identify the appropriate selection criteria for patients...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Medtech Insight

Even ‘Small’ Leaks After Left Atrial Appendage Occlusion Raises Stroke Risk, Study Finds

 
• By Brian Bossetta

A Japanese study of Watchman LAA closure devices found that leaks of any size after implantation raise the risk of stroke. The study comes shortly after the US FDA issued an early alert for the Watchman access systems.

23andMe Genetic Tests Among 12 New FDA Classifications

 
• By Elizabeth Orr

A late-August batch of device classifications from the US FDA includes genetic tests from 23andMe, hand-held spinal surgery tools, and several IVDs.

German Hospital Reform Risks Spiraling Out Of Control

 
• By Ashley Yeo

Amendments to Germany’s – barely in force – health reform law will be decided after the summer break. The new DRGs payments plan and service groups will be reviewed, but critics fear for the law’s future.